Tomorrow, Thursday, 17 November, industry leaders will meet in London for Emerging Innovations in Psychedelic Healthcare, to evaluate milestones in
Tomorrow, Thursday, 17 November, industry leaders will meet in London for Emerging Innovations in Psychedelic Healthcare, to evaluate milestones in
Psych Capital Plc is pleased to announce the appointment of the Conservative Drug Policy Reform Group (CDPRG) representative, Crispin Blunt
Psychedelic medicines are entering the latter stages of drug development, progressing from Phase II to Phase III trials, with the
It is a pivotal time for Small Pharma, as it anticipates data from its Phase IIa trial with lead candidate
In March, the Washington State legislature passed Senate Bill 5660, directing Washington State Health Care Authority to assess the provision
For The Psychedelics as Medicine Report: Fourth Edition, PSYCH spoke with Dr Laura Squire, Chief Healthcare Quality and Access Officer
On 8 November, over one million people in Colorado voted in favour of the Natural Medicine Health Act, Proposition 122,
Psychiatrist Dr Ben Sessa, Head of Psychedelic Medicine at Awakn Life Sciences, specialises in addiction services and psychedelic-assisted therapy. PSYCH
Earlier this month Biocase secured a licence from the Brazilian Ministry of Education, to train psychedelic-assisted therapists at Alma Viva
Double-blind randomised clinical trials A double-blind randomised clinical trial prevents bias when evaluating patient outcomes, validating the research. It is
PSYCH spoke with Angela Allbee, Oregon Psilocybin Services Section Manager at Oregon Health Authority, for The Psychedelics as Medicine Report:
In July, Ann Shulgin passed away following a long battle with lung disease. Alongside late husband Alexander Shulgin, Ann detailed